These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21056001)

  • 1. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
    Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
    J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
    Johnson JA; Li JF; Wei X; Lipscomb J; Irlbeck D; Craig C; Smith A; Bennett DE; Monsour M; Sandstrom P; Lanier ER; Heneine W
    PLoS Med; 2008 Jul; 5(7):e158. PubMed ID: 18666824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
    Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
    Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.
    Metzner KJ; Leemann C; Di Giallonardo F; Grube C; Scherrer AU; Braun D; Kuster H; Weber R; Guenthard HF
    PLoS One; 2011; 6(7):e21734. PubMed ID: 21754996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
    Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
    J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
    Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
    Metzner KJ; Scherrer AU; Preiswerk B; Joos B; von Wyl V; Leemann C; Rieder P; Braun D; Grube C; Kuster H; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    J Infect Dis; 2013 Oct; 208(7):1102-12. PubMed ID: 23847055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
    Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
    J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
    Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART.
    Nannyonjo M; Omooja J; Bugembe DL; Bbosa N; Lunkuse S; Nabirye SE; Nassolo F; Namagembe H; Abaasa A; Kazibwe A; Kaleebu P; Ssemwanga D
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
    Li H; Zhong M; Guo W; Zhuang D; Li L; Liu Y; Bao Z; Liu S; Wang X; Li T; Yang S; Li J
    PLoS One; 2013; 8(8):e72630. PubMed ID: 24009694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
    Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
    J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.